[Biolojic in BioSpace] Interim results from phase 1/2 clinical trial in solid tumor cancers demonstrate Aulos Bioscience’s AU-007 is well tolerated and uniquely reduces regulatory T Cells

LARKSPUR, Calif.–(BUSINESS WIRE)– Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today shared interim results from an ongoing Phase 1/2 trial of AU-007, as detailed in the online publication of Abstract e14507 at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.

Read more here.